Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 178Endometrial Neoplasms 110Uterine Cervical Neoplasms 100Breast Neoplasms 58Colorectal Neoplasms 49Fallopian Tube Neoplasms 45Carcinoma, Non-Small-Cell Lung 42Neoplasms 36Pancreatic Neoplasms 34Prostatic Neoplasms 27Neoplasm Metastasis 27Stomach Neoplasms 25Melanoma 25Squamous Cell Carcinoma of Head and Neck 22Lung Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 20Triple Negative Breast Neoplasms 19Carcinoma, Renal Cell 18Urinary Bladder Neoplasms 17Head and Neck Neoplasms 17Colonic Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma, Hepatocellular 15Small Cell Lung Carcinoma 14Sarcoma 14Cholangiocarcinoma 14Uterine Neoplasms 13Vulvar Neoplasms 12Rectal Neoplasms 12

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Gynecologic × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡